No products in the cart.
Pre-made Moxetumomab benchmark antibody ( Fv Fusion, anti-CD22 therapeutic antibody, Anti-SIGLEC2/SIGLEC-2 Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-358
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Moxetumomab biosimilar, Fv Fusion, Anti-CD22 Antibody: Anti-SIGLEC2/SIGLEC-2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Moxetumomab pasudotox-tdfk injection is used to treat hairy cell leukemia that has worsened or cannot be completely removed in patients who have had at least two previous treatments that did not work well.
| Products Name (INN Index) | Pre-Made Moxetumomab biosimilar, Fv Fusion, Anti-CD22 Antibody: Anti-SIGLEC2/SIGLEC-2 therapeutic antibody |
|---|---|
| INN Name | Moxetumomab |
| Target | CD22 |
| Format | Fv Fusion |
| Derivation | NA |
| Species Reactivity | Human |
| CH1 Isotype | NA |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | NFD |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2009 |
| Year Recommended | 2010 |
| Companies | National Cancer Institute (USA),AstraZeneca,M. D. Anderson Cancer Center,MedImmune,National Cancer Institute (USA) |
| Conditions Approved | Hairy cell leukaemia |
| Conditions Active | NA |
| Conditions Discontinued | Chronic lymphocytic leukaemia,Non-Hodgkin's lymphoma,Precursor B-cell lymphoblastic leukaemia-lymphoma,Precursor cell lymphoblastic leukaemia-lymphoma |
| Development Tech | CAT Phage Display |
| Previous Name | NA |
| Gm Offical Target Name | CD22 |
| Package |
Previous slide
Next slide
